This first-in-human study will be counducted to evaluate the safety, tolerability,
pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive
Locally Advanced or Metastatic Solid Tumors.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05523947.
Locations matching your search criteria
United States
Tennessee
Nashville
Vanderbilt University/Ingram Cancer CenterStatus: Active
Name Not Available
YH32367, a novel HER2/4-1BB bispecific antibody (BsAb), simultaneously targets HER2 and
h4-1BB and binds to both targets. YH32367 exhibits a strong 4-1BB signal activation as
well as blocking of HER2 signaling in HER2-expressing tumor cells. YH32367 stimulates
IFN-γ secretion from T cells and thereby induces tumor cells lysis.
This is a Phase 1/2, open-label, multicenter, first-in-human study of YH32367. This
2-part study will include both a Dose Escalation part, to identify the Maximum Tolerated
Dose (MTD) and/or two dose levels for RP2D selection, and a Dose Expansion part, to
determine RP2D and to confirm the safety, tolerability and efficacy of YH32367 at the
RP2D.
Lead OrganizationYuhan Corporation
